We at AOP Orphan are European pioneers in the field of rare diseases, researching, developing, producing, and distributing innovative solutions worldwide since 1996. Learn more about the company here.
We at AOP Orphan focus on rare diseases particularly in the areas of HematoOncology, Cardiology & Pulmonology, Neurology & Metabolic Disorders. Learn more about the indications, its symptoms, diagnosis, therapies and everyday life here.
Our strategic goal at AOP Orphan is to constantly deliver new treatment options for the patients with rare disease. Learn more about the current product portfolio and countries' availability here.
Agile, ambitious and aligned team members, mutual appreciation and commitment - this is what makes AOP Orphan a successful company and great place to work. Learn more about the company, open positions and everyday life at AOP Orphan here.
"I wanted to experience the joy of living, having positive thoughts again.“
Dr. Elena Zagorulko, PV Patient | Head of the MPN Support Group Austria
Narcolepsy Awareness Day 2020
Supporting Myeloproliferative Neoplasms (MPN) Awareness Day on Sep 10, 2020
AOP Orphan Statement on SARS-CoV-2 and COVID-19
ESH - Annual CCML
CPhI: Festival of Pharma
AOP Orphan team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe.
In the field of rare diseases the AOP Orphan team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.